RougeTx is a biotech developing first-in-class small-molecule therapies for vascular diseases caused by pericyte dysfunction.
RougeTx has raised $58.0M in total funding. The most recent round was Series A. The last funding was announced in October 2026.
RougeTx's investors include European Investment Bank, Kurma Partners, Epidarex Capital, BioGeneration Ventures, Vesalius Biocapital Partners.
RougeTx is headquartered in Naarden, The Netherlands.
RougeTx is a biotech developing first-in-class small-molecule therapies for vascular diseases caused by pericyte dysfunction.
RougeTx is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"RougeTx — Funding & Investors." VCBacked, October 6, 2026, https://www.vcbacked.co/company/rougetx. Accessed November 14, 2026.
VCBacked. (2026). RougeTx — Funding & Investors. Retrieved November 14, 2026, from https://www.vcbacked.co/company/rougetx
{{cite web |title=RougeTx — Funding & Investors |url=https://www.vcbacked.co/company/rougetx |website=VCBacked |access-date=November 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at RougeTx? Request a listing update